{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["32(3)"],"submitter":["Melero I"],"funding":["F. Hoffmann-La Roche Ltd"],"pubmed_abstract":["<h4>Purpose</h4>Cergutuzumab amunaleukin (CA) is an immunocytokine comprising a variant form of interleukin 2 (IL2) [constructed to avoid CD25 binding and regulatory T-cell (Treg) stimulation] fused to a carcinoembryonic antigen (CEA)-targeted antibody. This phase Ib open-label, multicenter dose-escalation and -expansion study (NCT02350673) evaluated the safety, activity, pharmacokinetics, and pharmacodynamics of CA plus atezolizumab in patients with advanced/metastatic CEA-positive solid tumors.<h4>Patients and methods</h4>Patients received escalating doses of CA (6-20/25 mg) with fixed dosages of atezolizumab (840 mg) every 2 weeks or escalating dosages of CA weekly (10-15/20 mg) with fixed dosages of atezolizumab (1,200 mg) every 3 weeks. Primary objectives include maximum tolerated dos"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pagination":["528-539"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12869162"],"repository":["biostudies-literature"],"pubmed_title":["Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors."],"pmcid":["PMC12869162"],"pubmed_authors":["Hafez N","Teichgraber V","Lassen U","O'Reilly EM","Evers S","Melero I","Martinez Quetglas I","Robbrecht DGJ","Boetsch C","Peters S","Adessi C","Steeghs N","Leighl N","Dejardin D","Rossmann E","Charo J","Tabernero J","Eefsen RL","Babitzki G","Cervantes A","Rizvi NA","Habigt C","Andersson E","Duarte J","Calvo E"],"additional_accession":[]},"is_claimable":false,"name":"Cergutuzumab Amunaleukin in Combination with Atezolizumab in Patients with Carcinoembryonic Antigen-Positive Advanced/Metastatic Solid Tumors.","description":"<h4>Purpose</h4>Cergutuzumab amunaleukin (CA) is an immunocytokine comprising a variant form of interleukin 2 (IL2) [constructed to avoid CD25 binding and regulatory T-cell (Treg) stimulation] fused to a carcinoembryonic antigen (CEA)-targeted antibody. This phase Ib open-label, multicenter dose-escalation and -expansion study (NCT02350673) evaluated the safety, activity, pharmacokinetics, and pharmacodynamics of CA plus atezolizumab in patients with advanced/metastatic CEA-positive solid tumors.<h4>Patients and methods</h4>Patients received escalating doses of CA (6-20/25 mg) with fixed dosages of atezolizumab (840 mg) every 2 weeks or escalating dosages of CA weekly (10-15/20 mg) with fixed dosages of atezolizumab (1,200 mg) every 3 weeks. Primary objectives include maximum tolerated dos","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-15T06:07:50.3Z","creation":"2026-07-01T03:07:45.314Z"},"accession":"S-EPMC12869162","cross_references":{"pubmed":["41252574"],"doi":["10.1158/1078-0432.CCR-25-2440"]}}